Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag [Seeking Alpha]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Seeking Alpha
Their lead agent, lirafugratinib, is being tested for intrahepatic cholangiocarcinoma and has shown promising results in early clinical studies. The company also has a pipeline project targeting mutated PI3K-alpha and another molecule, GDC-1971, which has been outlicensed to Genentech. Topline Summary Relay Therapeutics ( NASDAQ: RLAY ) is a clinical-stage biotech working on novel small molecule inhibitors of different actionable targets in cancer medicine. Using computational molecular dynamics, they hope to improve on targeted therapies through exquisite understanding of interactions between proteins and potential drugs of interest. Their lead agent of interest is an inhibitor of FGFR that is targeted toward an uncommon form of liver cancer, and they have other interesting targeted irons in the fire. The pipeline's hype has driven a lot of interest in the stock, striking a valuation over $1 billion (driven in large part to the company's massive coffers). I think there's a l
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate HighlightsGlobeNewswire
- Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024GlobeNewswire
- Relay Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
RLAY
Earnings
- 5/2/24 - Beat
RLAY
Analyst Actions
- 2/22/24 - Stifel
RLAY
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/29/24 - Form 4
- RLAY's page on the SEC website